Clinical Trial Update: A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the immunogenicity and safety of three consecutive production lots of IMVAMUNE (MVA-BN) smallpox vaccine in healthy vaccinia-naïve adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: Bavarian Nordic | Conditions: Smallpox | Phase 3 | Status: COMPLETED | Results posted: 2019-01-03